Treatment of leishmaniasis with chemotherapy and vaccine: a mathematical model

References

• M. Akdis, S. Burgler, R. Crameri, T. Eiwegger, H. Fujita, E. Gomez, S. Klunker, N. Meyer, L. O'Mahony, O. Palomares, C. Rhyner, N. Quaked, A. Schaffartzik, W.V.D. Veen, S. Zeller, M. Zimmermann, and C.A. Akdis, Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases, J. Allergy Clin. Immunol. 127 (2011), pp. 701–721.
   PubMed Web of Science ®Google Scholar
• J. Alexander and F. Brombacher, T Helper1/T Helper2 cells andresistance/susceptibility to Leishmania infection: Is this paradigm still relevant?, Front. Immunol. 3 (2012), pp. 1–13.
   PubMed Web of Science ®Google Scholar
• Q. Alfaham and A.A.J. Aljanaby, Interleukin 12 has an important role in patients infected with mycobacterium tuberculosis, Int. J. Pharm. Res. 2020 (2020), pp. 1448–1453.
   Google Scholar
• C. Antwi-Boasiako and A.D. Campbell, Low nitric oxide level is implicated in sickle cell disease and its complications in ghana, Vasc. Health Risk Manag. 14 (2018), pp. 199–204.
   PubMed Web of Science ®Google Scholar
• E. Bajetta, M.D. Vechio, R. Mortarini, R. Nadeau, A. Rakhit, L. Rimassa, C. Fowst, A. Borri, A. Anichini, and G. Parmiani, Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma, Clin. Cancer Res. 4 (1998), pp. 75–85.
   PubMed Web of Science ®Google Scholar
• J. Barbi, H.M. Snider, N. Bhardwaj, C.M.L. Davila, J.E. Durbin, and A.R. Sastokar, Signal transducer and activator of transcription 1 in T cells plays an indispensable role in immunity to Leishmania major by mediating Th1 cell homing to the site of infection, FASEB J. 23 (2009), pp. 3990–3999.
   PubMed Web of Science ®Google Scholar
• J.M. Basu and S. Roy, Sodium antimony gluconate (SAG) mediates antileishmanial effect by stimulating innate and cellular arms of the immune system, Sci. Cult. 73 (2007), pp. 138–143.
   Google Scholar
• M. Berktas, H. Guducuoglu, H. Bozkurt, K.T. Onbasi, M.G. Kurtoglu, and S. Andic, Change in serum concentrations of interleukin-2 and interferon-gamma during treatmentof tuberculosis, J. Int. Med. Res. 32 (2004), pp. 324–330.
   PubMed Web of Science ®Google Scholar
• J.D. Berman, D.M. Dwyer, and A.J. Wyler, Multiplication of leishmania in human macrophages in vitro, Infect. Immun. 26 (1979), pp. 375–379.
   PubMed Web of Science ®Google Scholar
• S. Bertholet, H.L. Dikensheets, F. Sheikh, A.A. Gam, R.P. Donnelly, and R.T. Kenney, Leishmania donovani-induced expression of suppressor of cytokine signaling 3 in human macrophages: A novel mechanism for intracellular parasite suppression of activation, Infect. Immun. 71 (2003), pp. 2095–2101.
   PubMed Web of Science ®Google Scholar
• BioXcel Corporation, Drugs & Diseases: Sodium Stibogluconate (rx), Medscape, 2023. Available at https://reference.medscape.com/drug/pentostam-stibogluconate-sodium-342669
   Google Scholar
• S.E. Borborema, J.A. Osso Jr, H.F. Andrade Jr, and N. d Nascimento, Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania)infantum chagasi-infected BALB/c mice, Mem. Inst. Oswaldo Cruz 108 (2013), p. 623–630.
   PubMed Web of Science ®Google Scholar
• O. Brandonisio, M.A. Panaro, M. Sisto, A. Acquafredda, L.F.D. Leogrande, and V. Mitolo, Nitric oxide production by leishmania-infected macrophages and modulation by cytokinesand prostaglandins, Parassitologia 43 (2001), pp. 1–6.
   PubMedGoogle Scholar
• A.M. Carvalho, A. Magalhães, L.P. Carvalho, O. Bacellar, P. Scott, and E.M. Carvalho, Immunologic response and memory t cells in subjects cured of tegumentaryleishmaniasis, BMC Infect. Dis. 13 (2013), pp. 529–536.
   PubMed Web of Science ®Google Scholar
• CDC, Parasites -- Leishmaniasis: Resources for Health Professionals, Global Health, Division of Parasitic Diseases and Malaria, 2023.
   Google Scholar
• J. Chakravarty, S. Kumar, S. Trivedi, V.K. Rai, A. Singh, J.A. Ashman, E.M. Laughlin, R.N. Coler, S.J. Kahn, A.M. Beckmann, K.D. Cowgill, S.G. Reed, S. Sundar, and F.M. Piazza, A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccinefor use in the prevention of visceral leishmaniasis, Vaccine 29 (2011), pp. 3531–3537.
   PubMed Web of Science ®Google Scholar
• M.M. Chan, N. Adapala, and C. Chen, Peroxisome proliferator-activated receptor-γ-mediated polarization of macrophages in leishmaniaInfection, PPAR Res. 2012 (2012), pp. 1–11.
   Web of Science ®Google Scholar
• K.P. Chang and D.M. Dwyer, Hamster macrophage interactions in vitro: Cell entry, intracellular survival, and multiplication of amastigotes, J. Exp. Med. 147 (1978), pp. 515–530.
   PubMed Web of Science ®Google Scholar
• T. Chanmee, P. Ontong, K. Konno, and N. Itano, Tumor-associated macrophages as major players in the tumor microenvironment, Cancers 6 (2014), pp. 1670–1690.
   PubMed Web of Science ®Google Scholar
• E.D. Crouser, K.S. Knox, M.W. Julian, G. Shao, S. Abraham, S. Liyanarachchi, J.E. Macre, M.D. Wewers, M.A. Gavrilin, P. Ross, A. Abbas, and C. Eng, Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis, Am. J. Respir. Crit. Care Med. 179 (2009), pp. 929–938.
   PubMed Web of Science ®Google Scholar
• J. Delgado-Dominguez, H. Gonzales-Aguilar, M. Ahuirre-Garcia, L. Gutierrez-Kobeh, M. Berzunza-Cruz, A. Ruiz-Remigio, M. Robles-Flores, and I. Becker, Leishmania mexicana lipophosphoglycan differentially regulates PKCα-induced oxidative burst inmacrophages of BALB/c and C57BL/6 mice, Paras. Immunol. 32 (2010), pp. 440–449.
   PubMed Web of Science ®Google Scholar
• S. Dhanji and H.S. Teh, Il-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells, J. Immunol. 171 (2003), pp. 3442–3450.
   PubMed Web of Science ®Google Scholar
• N. Didwania, M. Shadab, A. Sabur, and N. Ali, Alternative to chemotherapy—The unmet demand against leishmaniasis, Front. Immunol. 8 (2017), pp. 1779–1790.
   PubMed Web of Science ®Google Scholar
• J.H. Donohue and S.A. Rosenberg, The fate of interleukin-2 after in vivo administration, J. Immunol. 130 (1983), pp. 2203–2208.
   PubMed Web of Science ®Google Scholar
• M.S. Duthie, V.S. Raman, F.M. Piazza, and S.G. Reed, The development and clinical evaluation of second-generation leishmaniasis vaccines, Vaccine 30 (2012), pp. 134–141.
   PubMed Web of Science ®Google Scholar
• M.A. Elmekki, M.M. Elhassan, H.A. Ozbak, and M.M. Mukhtar, Elevated TGF-beta levelsin drug-resistant visceral leishmaniasis, Ann. Saudi Med. 36 (2016), pp. 73–77.
   PubMed Web of Science ®Google Scholar
• I. Esfandiarpour, S. Farajzadeh, Z. Rahnama, E.A. Fathabadi, and A. Heshmatkhah, Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int. J. Dermatol. 51 (2012), pp. 1221–1225.
   PubMed Web of Science ®Google Scholar
• F. Frézard, P.S. Martins, M.C. Barbosa, A.M. Pimenta, W.A. Ferreira, J.E. de Melo, J.B. Mangrum, and C. Demicheli, New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate, J. Inorg. Biochem. 102 (2008), pp. 656–665.
   PubMed Web of Science ®Google Scholar
• R. Garg, N. Singh, and A. Dube, Intake of nutrient supplements affects multiplication of leishmania donovani in hamsters, Parasitology 129 (2004), pp. 685–691.
   PubMed Web of Science ®Google Scholar
• A. Ghasemi, S. Zahedi Asl, Y. Mehrabi, N. Saadat, and F. Azizi, Serum nitric oxide metabolite levels in a general healthy population: Relation to sex and age, Life Sci. 83 (2008), pp. 326–331.
   PubMed Web of Science ®Google Scholar
• M. Ghosh, K. Roy, and S. Roy, Immunomodulatory effects of antileishmanial drugs, J. Antimicrob. Chemother. 68 (2013), pp. 2834–2838.
   PubMed Web of Science ®Google Scholar
• D. Gong, W. Shi, S.J. Yi, H. Chen, J. Groffen, and N. Heisterkamp, TGF-β signaling plays a critical role in promoting alternative macrophage activation, BMC Immunol. 13 (2012), pp. 31–40.
   PubMed Web of Science ®Google Scholar
• S.J. Green, M.S. Meltzer, J.B.H. Jr, and C.A. Nacy, Activated macrophages destroy intracellular leishmania major amasgtigotes by an L-aarginine-dependent killing mechanism, J. Immunol. 144 (1990), pp. 278–283.
   PubMed Web of Science ®Google Scholar
• A.P.C. Gélvez, J.A.P. Diniz Junior, R.T.S. Santa Brígida, and A.P.D. Rodrigues, AgNP-PVP-meglumine antimoniate nanocomposite reduces leishmania amazonensis infection in macrophages, BMC Microbiol. 21 (2021), pp. 211–224.
   PubMed Web of Science ®Google Scholar
• M.A. Gómez, A. Navas, M.D. Prieto, L. Giraldo-Parra, A. Cossio, N. Alexander, and N.Gore Saravia, Immuno-pharmacokinetics of meglumine antimoniate in patients with cutaneous leishmaniasis caused by leishmania (Viannia), Clin. Infect. Dis. 72 (2021), pp. e484–e492.
   PubMed Web of Science ®Google Scholar
• T.S. Hakim, K. Sugimori, E.M. Camporesi, and G. Anderson, Half-life of nitric oxide in aqueous solutions with and without haemoglobin, Physiol. Meas. 17 (1996), pp. 267–277.
   PubMed Web of Science ®Google Scholar
• A.K. Haldar, P. Sen, and S. Roy, Use of antimony in the treatment of leishmaniasis: Current status and future directions, Mol. Biol. Int. 2011 (2011), pp. 1–23.
   Google Scholar
• E. Handman and D.T. Spira, Growth of leishmania amastigotes in macrophages from normal and immune mice, Z. Parasitenk. 53 (1977), pp. 75–81.
   PubMed Web of Science ®Google Scholar
• W. Hao, E.D. Crouser, and A. Friedman, Mathematical model of sarcoidosis, PNAS 111 (2014), pp. 16065–16070.
   PubMed Web of Science ®Google Scholar
• R.L. Hengel, B.M. Jones, M.S. Kennedy, M.R. Hubbard, and J.S. McDougal, Markersof lymphocyte homing distinguish CD4 T cell subsets that turn overin response to HIV-1 infection in humans, J. Immunol. 163 (1999), pp. 3539–3548.
   PubMed Web of Science ®Google Scholar
• C.J. Henry, D.A. Ornelles, L.M. Mitchell, K.L. Brzoza-Lewis, and E.M. Hiltbold, IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17, J. Immunol. 12 (2008), pp. 8576–8584.
   Google Scholar
• M.F. Horta, B.P. Mendes, E.H. Roma, F.S.M. Noronha, J.P. Macêdo, L.S. Oliveira, M.M. Duarte, and L.Q. Vieira, Reactive oxygen species and nitric oxide in cutaneous leishmaniasis, J. Paras. Res. 2012 (2012), pp. 315–326.
   Google Scholar
• I. Jomantaite, N. Dikopoulos, A. Kroger, F. Leithauser, H. Hauser, R. Schirmbeck, and J. Reimann, Hepatic dendritic cell subsets in the mouse, Eur. J. Immunol. 34 (2004), pp. 355–365.
   PubMed Web of Science ®Google Scholar
• E. Jonasch and F.G. Haluska, Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities, Oncologists 6 (2001), pp. 34–55.
   PubMed Web of Science ®Google Scholar
• M. Khodoum, C. Lewis, J.Q. Yang, T. Orekov, C. Potter, T. Wynn, M. Mentink-Kane, G.K.K. Hershey, M. Wills-Karp, and F.D. Finkelman, Differences in expression, affinity,and function of soluble (s)IL-4Rα and sIL-13Rα2 suggest opposite effects on allergic responses, J. Immunol. 179 (2007), pp. 6429–6438.
   PubMed Web of Science ®Google Scholar
• K.A. Kigerl, J.C. Gensel, D.P. Ankeny, J.K. Alexander, D.J. Donnelly, and P.G. Popovich, Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord, J. Neurosci. 43 (2009), pp. 13435–13444.
   Google Scholar
• D.E. Kirschner, Uncertainty and Sensitivity Functions and Implementation, Source code, University of Michigan, 2007–2008. Available at http://malthus.micro.med.umich.edu/lab/usadata/.
   Google Scholar
• A. Kocyigit, S. Gur, M.S. Gurel, V. Bulut, and M. Ulukanligil, Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis, Infect. Immun. 70 (2002), pp. 6589–6591.
   PubMed Web of Science ®Google Scholar
• R.C. Kuschnir, L.S. Pereira, M.R.T. Dutra, L. de Paula, M.L. Silva-Freitas, G. Corrêa-Castro, S. da Costa Cruz Silva, G. Cota, J.R. Santos-Oliveira, and A.M. Da-Cruz, High levels of anti-leishmania igg3 and low cd4+ t cells count were associated with relapses in visceral leishmaniasis, BMC Infect. Dis. 21 (2021), pp. 369.
   PubMed Web of Science ®Google Scholar
• H. Lagler, M. Willheim, F. Traunmuller, K. Wahl, H. Winkler, M. Ramharter, W. Graninger, and andS. Winkler, Cellular profile of cytokine production in a patient with visceral leishmaniasis: γδ+ T cells express both type 1 cytokines and interleukin-10, Scan. J. Immunol. 57 (2003), pp. 291–295.
   PubMed Web of Science ®Google Scholar
• T. Le, L. Leung, W.L. Carroll, and K.R. Shibbler, Regulation of interleukin-10 gene expression: Possible mechanisms accounting for its up regulation and for maturational differences in its expression by blood mononuclear cells, Blood 89 (1997), pp. 4112–4119.
   PubMed Web of Science ®Google Scholar
• F.Y. Liew, C. Parkinson, S. Millott, A. Severn, and M. Carrier, Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis, Immunology 69 (1990), pp. 570–573.
   PubMed Web of Science ®Google Scholar
• D. Liu and J.E. Uzonna, The early interaction of leishmania with macrophages and dendritic cells and its influence on the host immune response, Front. Cell. Infect. Microbiol. 2 (2012), pp. 83–90.
   PubMed Web of Science ®Google Scholar
• Z. Liu, W. Kuang, Q. Zhou, and Y. Zhang, TGF-β1 secreted by m2 phenotype macrophages enhances the stemness and migration of glioma cells via the smad2/3 signalling pathway, Int. J. Mol. Med. 42 (2018), pp. 3395–3403.
   PubMed Web of Science ®Google Scholar
• H.L. Lu, X.Y. Huang, Y.F. Luo, W.P. Tan, P.F. Chen, and Y.B. Guo, Activation of m1macrophages plays a critical role in the initiation of acute lung injury, Biosci. Rep. 38 (2018), pp. BSR20171555.
   PubMed Web of Science ®Google Scholar
• M.L. Lohmann-Matthes, B. Lüttig, and S. Hockertz, Involvement of membrane-associated TNF in the killing of leishmania donovani parasites by macrophages, Behring Inst. Mitt. 88 (1991), pp. 125–132.
   Google Scholar
• Mandell, Douglas, and Bennett, Principles and Practice of Infectious Diseases: Antimonygluconate, Saunders 8th, 2015.
   Google Scholar
• P.P. Manna, S.K. Hira, A. Basu, and S. Bandyopadhyay, Cellular therapy by allogeneic macrophages against visceral leishmaniasis: Role of TNF-α, Cell. Immunol. 290 (2014), pp. 152–163.
   PubMed Web of Science ®Google Scholar
• A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol. 25 (2004), pp. 677–686.
   PubMed Web of Science ®Google Scholar
• S. Marino, I.B. Hogue, C.J. Ray, and D.E. Kirschner, A methodology for performing global uncertainty and sensitivity analysis in systems biology, J. Theor. Biol. 254 (2008), pp. 178–196.
   PubMed Web of Science ®Google Scholar
• F.O. Martinez, Regulators of macrophage activation, Eur. J. Immunol. 41 (2011), pp. 1531–1534.
   PubMed Web of Science ®Google Scholar
• A.K. Mehta, D.T. Gracias, and M. Croft, TNF activity and T cells, Cytokine 101 (2018), pp. 14–18.
   PubMed Web of Science ®Google Scholar
• L. Ming-Cai and H. Shao-Heng, Il-10 and its related cytokines for treatment of inflammatory bowel disease, World J. Gastroentorol. 10 (2015), pp. 620–625.
   Google Scholar
• M. Moafi, H. Rezvan, R. Sherkat, and R. Taleban, Leishmania vaccines entered in clinical trials: A review of literature, Int. J. Prev. Med. 10 (2019), pp. 134–141.
   PubMed Web of Science ®Google Scholar
• E. Nascimento, D.F. Fernandes, E.P. Vieira, A. Campos-Neto, J.A. Ashman, F.P. Alves, R.N. Coler, L.Y. Bogatzki, S.J. Kahn, A.M. Beckmann, S.O. Pine, K.D. Cowgill, S.G. Reed, and F.M. Piazza, A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SEVACCINE when used in combination with meglumine antimoniate for the treatment of cutaneousleishmaniasis, Vaccine 28 (2010), pp. 6581–6587.
   PubMed Web of Science ®Google Scholar
• E. Obeid, R. Nanda, Y.X. Fu, and O.I. Olopade, The role of tumor-associated macrophages in breast cancer progression (review), Int. J. Oncol. 43 (2013), pp. 5–12.
   PubMed Web of Science ®Google Scholar
• J.C. Oliver, L.A. Bland, C.W. Oettinger, M.J. Arduino, S.K. McAllister, S.M. Aguero, and M.S. Favero, Cytokines kinetics in an in vitro whole blood model following an endotoxin challenge, Lymphokine Cytokine Res. 12 (1993), pp. 115–120.
   PubMedGoogle Scholar
• A.L. Oliveira, Y.M. Brustoloni, T.D. Fernandes, M.E. Dorval, R.V. Cunha, and M.N. Bóia, Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: A report of 13 cases in the southwestern region of Brazil, Trop. Doct. 39 (2009), pp. 180–182.
   PubMed Web of Science ®Google Scholar
• C.M.S. Pacheco, G.V.A. Flores, K. Gonzalez, C.M. de Castro Gomes, L.F.D. Passero, T.Y. Tomokane, W. Sosa-Ochoa, C. Zúniga, J. Calzada, A. Saldaña, C.E.P. Corbett, F.T. Silveira, and M.D. Laurenti, Macrophage polarization in the skin lesion caused by neotropical species of leishmania sp, J. Immunol. Res. 2021 (2021), pp. 5596876–5596883.
   PubMed Web of Science ®Google Scholar
• M.A. Panaro, O. Brandonisio, A. Cianciulli, P. Cavallo, V. Lacasella, P. Paradies, G. Testini, D.de Caprariis, V. Mitolo, and D. Otranto, Cytokine expression in dogs with natural Leishmania infantum infection, Parasitoly 136 (2009), pp. 823–831.
   PubMed Web of Science ®Google Scholar
• N. Parameswaran and S. Patial, Tumor necrosis factor-α signaling in macrophages, Crit. Rev. Eukaryot Gene Expr. 20 (2010), pp. 87–103.
   PubMed Web of Science ®Google Scholar
• R. Phillips, M. Svensson, N. Aziz, A. Maroof, N. Brown, L. Beattie, N. Signoret, and P.M. Kaye, Innate killing of leishmania donovani by macrophages of the splenic marginal zone requires IRF-7, PLoS Pathog. 6 (2010), pp. 1–13.
   Web of Science ®Google Scholar
• S. Pradhan, R.A. Schwartz, A. Patil, S. Grabbe, and M. Goldust, Treatment options for leishmaniasis, Clin. Exp. Dermatol. 47 (2022), pp. 516–521.
   PubMed Web of Science ®Google Scholar
• V.S. Raman, M.S. Duthie, C.B. Fox, G. Matlashewski, and S.G. Reed, Adjuvants for leishmania vaccines: From models to clinical application, Front. Immunol. 3 (2012), pp. 144–158.
   PubMed Web of Science ®Google Scholar
• R.M. Reguera, Y. Pérez-Pertejo, C. Gutiérrez-Corbo, B. Domínguez-Asenjo, C. Ordóñez, C. García-Estrada, M. Martínez-Valladares, and R. Balaña-Fouce, Current and promising novel drug candidates against visceral leishmaniasis, Pure Appl. Chem. 91 (2019), pp. 1385–1404.
   Web of Science ®Google Scholar
• A. Sarkar, P. Saha, G. Mandal, D. Mukhopadhyay, S. Roy, S.K. Singh, S. Das, R.P. Goswami, B. Saha, D. Kumar, P. Das, and M. Chatterjee, Monitoring of intracellular nitric oxide in leishmaniasis: Its applicability in patients with visceral leishmaniasis, Cytometry A 79 (2011), pp. 35–45.
   PubMedGoogle Scholar
• N. Siewe and A. Friedman, Increase hemoglobin level in severe malarial anemia while controlling parasitemia: A mathematical model, Math. Biosci. 326 (2020), pp. 108374.
   PubMed Web of Science ®Google Scholar
• N. Siewe and A. Friedman, Tgf-β inhibition can overcome cancer primary resistance to pd-1 blockade: A mathematical model, PLoS ONE 16 (2021), pp. 1–16.
   Web of Science ®Google Scholar
• N. Siewe, A.A. Yakubu, A.R. Satoskar, and A. Friedman, Immune response to infection by leishmania: A mathematical model, Math. Biosci. 276 (2016), pp. 28–43.
   PubMed Web of Science ®Google Scholar
• N. Siewe, A.A. Yakubu, A.R. Satoskar, and A. Friedman, Granuloma formation in leishmaniasis: A mathematical model, J. Theor. Biol. 412 (2017), pp. 48–60.
   PubMed Web of Science ®Google Scholar
• R. Simó, A. Barbosa-Desongles, A. Lecube, C. Hernandez, and D.M. Selva, Potential role of tumor necrosis factor-α in down regulating sex hormone-binding globulin, Diabetes 61 (2012), pp. 372–382.
   PubMed Web of Science ®Google Scholar
• S.V. Spitsin, J.L. Farber, M. Bertovich, G. Moehren, H. Koprowski, and F.H. Michaels, Human- and mouse-inducible nitric oxide synthase promoters require activation of phosphatidylcholine-specific phospholipase C and NF-kappa B, Mol. Med. 3 (1997), pp. 315–326.
   PubMed Web of Science ®Google Scholar
• S. Srivastav, W.B. Ball, P. Gupta, J. Giri, A. Ukil, and P.K. Das, Leishmania donovani prevents oxidative burst-mediated apoptosis of host macrophages through selective induction of suppressors of cytokine signaling (SCOS) proteins, J. Biol. Chem. 289 (2014), pp. 1092–1105.
   PubMed Web of Science ®Google Scholar
• M. Stein, S. Keshav, N. Harris, and S. Gordon, Interleukin 4 potentially enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation, J. Exp. Med. 176 (1992), pp. 287–292.
   PubMed Web of Science ®Google Scholar
• B. Tirado-Rodriguez, E. Ortega, P. Segura-Medina, and S. Huerta-Yepez, TGF-β: An important mediator of allergic disease and a molecule with dual activity in cancer development, J. Immunol. Res. 2014 (2014), pp. 1–15.
   Web of Science ®Google Scholar
• S.R.B. Uliana, C.T. Trinconi, and A.C. Coelho, Chemotherapy of leishmaniasis: Present challenges, Parasitology 145 (2018), pp. 464–480.
   PubMed Web of Science ®Google Scholar
• R. van Furth, Cells of the mononuclear phagocyte system. Nomenclature in terms of sites and conditions, in Mononuclear Phogocytes: Functional Aspects. Part 1., R. van Furth, ed., Martinus Nijhoff Publishers, The Hague, 1980, pp. 1–30.
   Google Scholar
• J.F. Viallard, J.L. Pellegrin, V. Ranchin, T. Schaeverbeke, J. Dehais, M. Longy-Boursier, J.M. Ragnaud, B. Leng, and J.F. Moreau, Th1 (IL-2 interferon-gamma (IFN-gamma)) andTh2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic hupus erythematocus (SLE), Clin. Exp. Immunol. 115 (1999), pp. 189–195.
   PubMed Web of Science ®Google Scholar
• S. Vikrant, D. Gupta, and S.S. Kaushal, Sodium stibogluconate-associated acute interstitial nephritis in a patient treated for visceral leishmaniasis, Saudi J. Kidney Dis. Transpl. 26 (2015), pp. 757–760.
   PubMedGoogle Scholar
• I.D. Vélez, K. Gilchrist, S. Martínez, J.R. Ramírez-Pineda, J.A. Ashman, F.P. Alves, R.N. Coler, L.Y. Bogatzki, S.J. Kahn, A.M. Beckmann, K.D. Cowgill, S.G. Reed, and F.M. Piazza, Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis, Vaccine 28 (2009), pp. 329–337.
   PubMed Web of Science ®Google Scholar
• H.H. Wacker, R.J. Radzun, and M.R. Parwaresch, Kinetics of Kupffer cells as shown by parabiosis and combined autoradiographic/immunohistochemical analysis, Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 51 (1986), pp. 71–78.
   PubMedGoogle Scholar
• E.S. Wise, M.S. Armstrong, J. Watson, and D.N. Lockwood, Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with new world cutaneous leishmaniasis [corrected], PLoS Negl. Trop. Dis. 6 (2012), pp. e1688.
   PubMed Web of Science ®Google Scholar
• J.K. Wong, M.C. Strain, R. Prrata, E. Reay, S. Sankaran-Walters, C.C. Ignacio, T. Russell, S.K. Pillai, D.J. Looney, and S. Dandekar, In vivo cd8+ T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells, PLoS Pathog. 6 (2010), pp. 1–12.
   Web of Science ®Google Scholar
• X. Wu, W. Xu, X. Feng, Y. He, X. Liu, Y. Gao, S. Yang, Z. Shao, C. Yang, and Z. Ye, TNF-a mediated inflammatory macrophage polarization contributes to the pathogenesis of steroid-induced osteonecrosis in mice, Int. J. Immunopathol. Pharmacol. 28 (2015), pp. 351–361.
   PubMed Web of Science ®Google Scholar
• Y. Yesilova, H.A. Surucu, N. Ardic, M. Aksoy, A. Yesilova, S. Oghumu, and A.R. Satoskar, Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis, J. Dermatolog. Treat. 27 (2016), pp. 83–87.
   PubMed Web of Science ®Google Scholar
• P. Zanger, I. Kotter, P.G. Kremsner, and G. Gabrysch, Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe, Clin. Microb. Infect. 18 (2012), pp. 670–676.
   Google Scholar